Medicine guide
Rasilamlo
·
- Prescription status not stated
- Heart, blood pressure and circulation
- Active substance
- Aliskiren hemifumarate;amlodipine besilate
- Made by
- Novartis Europharm Ltd
- Source
- Official label
Quoted from the official source. Not yet reviewed by Mediclarum — the leaflet in your pack is authoritative.
What it is for
- Rasilamlo is indicated for the treatment of essential hypertension in adult patients whose blood pressure is not adequately controlled with aliskiren or amlodipine used alone.
From the official label · 2026-09-30 · European Medicines Agency
Details
| Made by | Novartis Europharm Ltd |
|---|---|
| Active substance | Aliskiren hemifumarate;amlodipine besilate |
| Used in | Heart, blood pressure and circulation |
| Classification | C09XA53 · Heart, blood pressure and circulation |
| Authorised on | 2011-04-14 |
| Last updated by the regulator | 2017-03-28 |
| EMA product number | EMEA/H/C/002073 |
Source: European Medicines Agency — medicine data · 2026-09-30 · not reviewed by a clinician
Source: European Medicines Agency (EMA). Product information as published by EMA. Reuse terms: EMA legal notice (reproduction authorised).